Our mission: to make complex medical testing simple and accessible wherever and whenever needed.

Orbis Diagnostics believes everyone should be empowered to understand their true health status, irrespective of who they are and where they live. High quality, accessible diagnostics enable individuals within society to make life-changing decisions with confidence. Established in 2016, Orbis brings together a proven team of world-leading researchers, backed by New Zealand’s largest early stage deep-tech investor, Pacific Channel. 

Orbis has developed a ‘lab on a disk’ testing platform that uses its microfluidic platform technology to miniaturise and automate accurate lab testing for use at points of need. Originally designed for the cowshed, the first product to run on this platform was able to accurately quantify progesterone in milk for heat detection, to inform the timing of artificial insemination. With the outbreak of COVID-19, Orbis recognised how the unique features of our system could help re-enable safe travel amidst a pandemic and quickly pivoted the company to develop a quantitative immunity test for COVID-19. 

February 2021
February 2021

Partnership with IDEMIA

Orbis announces an exclusive partnership with leading biometrics company IDEMIA to develop and deploy a complete immunity testing platform solution for the air travel industry that enables the best passenger experience without compromising on security.